



Prevalence of self-reported falls, balance or walking problems in older cancer survivors from Surveillance, Epidemiology and End Results—Medicare Health Outcomes Survey



Min H. Huang^{*}, Jennifer Blackwood, Monica Godoshian, Lucinda Pfalzer

Physical Therapy Department, School of Health Professions and Studies, University of Michigan – Flint, Flint, Michigan, United States

ARTICLE INFO

Article history:

Received 27 January 2017

Received in revised form 28 February 2017

Accepted 27 May 2017

Available online 8 June 2017

Keywords:

Geriatrics

Falls

Balance

Walking

Cancer

Prevalence

Survivorship

Population-based

ABSTRACT

Objective: To determine the prevalence of falls and balance/walking problems in the past 12 months among older cancer survivors before and after cancer diagnosis.

Materials and Methods: We analyzed cross-sectional data from individuals aged ≥ 65 years with first primary cancer from the Surveillance, Epidemiology, and End Results and Medicare Health Outcomes Survey (SEER-MHOS) linkage ($n = 12,659$). The first MHOS completed by each survivor from 0 to 2 years before cancer diagnosis to 1–4 years after cancer diagnosis were included. We estimated unadjusted and demographic-adjusted prevalence of falls and balance/walking problems for each type of cancer during five one-year time periods before and after cancer diagnosis.

Results: Adjusted prevalence of falls was significantly higher post-diagnosis than pre-diagnosis in prostate (12% during years 1–2 pre-diagnosis vs. 17%–20% during years 1–4 post-diagnosis) ($p = 0.01$) and lung cancer (17% during years 1–2 pre-diagnosis vs. 28% during years 1–2 post-diagnosis) ($p = 0.019$). **Adjusted prevalence of balance/walking problems were significantly higher post-diagnosis** than pre-diagnosis in non-Hodgkin's lymphoma (26% during years 1–2 pre-diagnosis vs. 45% during years 1–2 post-diagnosis) ($p = 0.012$), breast (32% during years 1–2 pre-diagnosis vs. 41% during years 3–4 post-diagnosis) ($p = 0.001$), prostate (22% during years 1–2 pre-diagnosis vs. 28%–29% during years 1–4 post-diagnosis) ($p = 0.012$), and lung cancer (33% during years 1–2 pre-diagnosis vs. 40% during year 0–1 pre-diagnosis and 46% during years 1–2 post-diagnosis) ($p = 0.018$). Prevalence did not differ across time periods in other cancers.

Conclusions: Falls and balance/walking problems may become more frequent after the diagnosis of some cancers. Screening, surveillance, and interventions need to consider functional deficits and cancer diagnosis.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Cancer is a chronic condition of older adults. About 53% of new cancers are diagnosed in people 65 years and older [1,2]. With recent advances in medical care, people are living longer after cancer treatments. The 5-year survival rate after the age of 65 years is 59% [3]. The number of cancer survivors is projected to reach 19 million by 2024 [4]. National expenditures for cancer care totaled nearly \$125 billion in 2010, and are estimated to cost \$156 billion in 2020 [5]. In light of the aging population and the increasing cost of care, developing strategies to optimize function along the trajectory of survivorship for older cancer survivors has become a significant challenge [6–9].

In older adults, falls are common occurrences with serious consequences, including increased cost of health care, mortality, poor quality of life, fears of falling, and restricted mobility [10–17]. Additionally, difficulty with balance or walking is associated with falls, dependence in activities of daily living, and lower quality of life [18–22]. A loss of balance contributed to more than 50% of falls among cancer survivors receiving neurotoxic chemotherapy [23]. Slow walking speed and impaired ability to walk 1/4 mile have been linked to heightened mortality and disability among older cancer survivors [24,25]. Cancer and its treatment impact multiple body systems and present unique health risks [4,23,26–29]. Accelerated aging is evidenced by greater declines in health outcomes over time after cancer diagnosis [30–33]. Significantly higher fall rates among older cancer survivors compared to those without cancer have been documented in population-based studies, with one reporting 33% vs. 30% (OR = 1.16, 95%CI, 1.01 to 1.33, $n = 9481$) [34] and another reporting 26% vs. 22% (OR = 1.17, 95%CI, 1.04 to 1.32, $n = 12,480$) [35]. Fall rates of older cancer survivors from previous studies ranged from 20% to 30% over 3 to 12 months

^{*} Corresponding author at: Physical Therapy Department, School of Health Professions and Studies, The University of Michigan-Flint, 2157 William S. White Building, 303 E. Kearsley St., Flint, MI 48502-1950, United States.

E-mail address: mhhuang@umflint.edu (M.H. Huang).

across different practice settings [29]. Difficulty with balance and walking were identified by cancer survivors as the most frequent functional problems, with prevalence of 19% and 24%, respectively [36]. While the sequelae vary with time and type of cancer [4,23,26–29], whether the prevalence of falls and balance/walking problems vary with time post-cancer diagnosis remains poorly understood. Such information is key for developing survivorship care plans to improve health outcomes and costs, satisfaction with treatment, and caregiver burden.

The aims of this study were to (1) determine unadjusted and demographic-adjusted prevalence of self-reported falls and balance/walking problems in the past 12 months among older cancer survivors from pre- to post-cancer diagnosis, and (2) investigate whether prevalence during initial and later time periods post-cancer diagnosis may be higher in comparison with prevalence during 1–2 years pre-cancer diagnosis. Using population-based data and a cross-sectional design, prevalence among survivors during five one-year time periods before and after cancer diagnosis were estimated for each of the eight common cancers.

2. Materials and Methods

2.1. Design

This was a cross-sectional study analyzing 2006–2013 data from the Surveillance, Epidemiology and End Results Program and the Medicare Health Outcomes Survey (SEER-MHOS) linkage [37]. The SEER collects information about all newly diagnosed cancer cases from 16 cancer registries that cover about 26% of the U.S. population. The SEER-MHOS linkage includes data from 14 cancer registries, including cancer type, stage, time of diagnosis, cancer histology, initial cancer treatment, such as surgery and radiation, survival time, and cause of death [37]. The MHOS is a 95-item questionnaire that gathers valid, reliable, clinically meaningful, and patient-reported outcomes, including demographics, socioeconomic status, health habits and problems, chronic conditions, functional status, symptoms, health-related quality of life, and respondent characteristics, to monitor the quality of care of Medicare Advantage organizations [37,38]. Beneficiaries in participating Medicare Advantage organizations (managed care health plans) are randomly sampled annually by mail or telephone, and then resurveyed 2 years later [37,38]. The response rates of the baseline survey ranged from 64.1% in 1998 to 71.6% in 2000 [37]. The follow-up response rates ranged from 76.3% to 84.9% [37]. The extent of potential nonresponse bias of the MHOS was reported to be minimal and does not adversely affect estimates of health status for this population [39].

2.2. Setting

Population-based.

2.3. Participants

Fig. 1 shows the inclusion of the study sample. The sample was comprised of individuals age ≥ 65 years from SEER-MHOS cohort 9–14, beginning on January 1st in 2006 and ending on December 31st in 2013. Data from survivors of non-Hodgkin's lymphoma (NHL), breast, prostate, colorectal, lung, kidney, bladder, or uterine cancers were extracted. These cancers are highly prevalent in older adults [1,40]. Inclusion criteria were: first primary cancer, availability of cancer staging information, and MHOS administered from years 0–2 before cancer diagnosis to years 1–4 after diagnosis. Because the MHOS asked about falls and balance/walking problems in the past 12 months, survivors completing the MHOS within the first year after cancer diagnosis could have fallen or experienced balance/walking problems before diagnosis. Therefore, these survivors were excluded. We included the first MHOS completed by each individual in the analyses.

2.4. Main Outcomes and Measures

Primary outcomes were falls and balance/walking problems based on two MHOS questions with responses of “yes” (coded as 1) or “no” (coded as 2): (1) “A fall is when your body goes to the ground without being pushed. Did you fall in the past 12 months?” (2) “In the past 12 months, have you had a problem with balance or walking?” The prevalence estimates of falls or balance/walking problems, respectively, were defined as the number of survivors responding “yes” to these two questions.

The difference in time from MHOS administration to cancer diagnosis was calculated to create a categorical “time period” variable (coded as 1: >1 year and ≤ 2 years pre-diagnosis, 2: ≤ 1 year pre-diagnosis, 3: >1 year and ≤ 2 years post-diagnosis, 4: >2 years and ≤ 3 years post-diagnosis, and 5: >3 years and ≤ 4 years post-diagnosis). Survivors were classified into these five “time period groups” within each cancer diagnosis based on when they completed the MHOS relative to the time of cancer diagnosis. We compared the prevalence estimates between different time periods for each cancer.

Demographics variables included age at MHOS survey, gender (male, female), race (white, black, other/unknown), marital status (married, not married), education ($<$ high school, high school or some college, ≥ 4 -year college), and household income ($<$ \$30,000, \$30,000–\$50,000, $>$ \$50,000, unknown).

Health-related variables included calculated body mass index (BMI) and comorbidity index. Thirteen chronic conditions were identified from the MHOS (arthritis, osteoporosis, chronic obstructive pulmonary condition, angina, congestive heart failure, myocardial infarct, stroke, hypertension, diabetes types I and II, visual impairment, hearing impairment, low back pain, and depression). Each was scored as 1 (with the condition) or 0 (without the condition). The sum of scores from all conditions was the comorbidity index.

Cancer-related variables included age at diagnosis, type of cancer, stage of cancer (in situ, localized, regional, distant) [41], time to diagnosis, radiation (yes, no/unknown), surgery (yes, no/unknown), and surgery with radiation (yes, no/unknown). The SEER-MHOS does not include chemotherapy or hormonal therapy information.

2.5. Statistical Analysis

Descriptive statistics were calculated for sample characteristics. Using Poisson regression with robust error variance [42–44], we included the “time period” variable as covariate to estimate the unadjusted and adjusted prevalence of falls and balance/walking problems during each of the five time periods from pre- to post-cancer diagnosis. Separate regression models were constructed for each cancer. In the adjusted analyses, an a priori selection of demographic variables (age at survey, race, marital status, education, and household income) was added to the models as covariates based on previous research evidence [45,46]. Gender was also included in these models, except in breast, prostate, and uterine cancer. We used simple contrast coding for the “time period” variable to compare the prevalence during a time period with the prevalence during 1–2 years pre-diagnosis, i.e. the reference prevalence. Bonferroni adjustments were applied for post-hoc comparisons of the prevalence during each time period with the reference prevalence. All analyses were performed with IBM-SPSS® Version 22 (Armonk, NY). All tests were 2-sided. The level of significance was set at 0.05.

3. Results

3.1. Sample Characteristics

As shown in Table 1, the mean age at the administration of MHOS ranged from 74.2 (SD = 5.8) years in prostate cancer to 77.5 (SD = 6.6) years in bladder cancer. The majority were white, married, and




Fig. 1. Flowchart of study population. The sample composed of individuals age ≥ 65 years from cohorts nine to fourteen (year 2006 to 2013) of the Surveillance, Epidemiology and End Results Program and the Medicare Health Outcomes Survey (SEER-MHOS) linkage. Inclusion criteria were: first, primary cancer (non-Hodgkin's lymphoma, breast, prostate, colorectal, lung, bladder, kidney, or uterine cancer), availability of cancer staging information, and first MHOS administered from 0 to 2 years before cancer diagnosis to 1–4 years after diagnosis. Data from the first MHOS completed by each individual were extracted. Responses to two MHOS questions about falls and balance/walking problems were analyzed to obtain prevalence estimates.

with high school or some college education. Most survivors (41.9% to 54.4%) had household incomes of less than \$30,000. Women accounted for 26.5% of survivors of bladder cancer. Approximately half of the survivors of NHL, colorectal, lung, and kidney cancer were men. Mean body mass index ranged from 25.9 (SD = 5.4) in lung cancer to 30.4 (SD = 7.6) in uterine cancer. Mean age at diagnosis ranged from 72.5 (SD = 6.0) years in prostate cancer to 76.2 (SD = 6.9) years in bladder cancer. Localized or regional cancer stage was the most frequent in breast, prostate, colorectal, bladder, kidney, and uterine cancer. About 46% and 51% of survivors with lung cancer and NHL, respectively, were at the advanced stage. The rates for radiation or surgery varied across cancers. Breast (47.8%) and uterine cancer (32.1%) had the highest rates of treatment with both radiation and surgery.

3.2. Prevalence of Falls in the Past 12 Months

As shown in Table 2, prevalence of falls differed significantly across time periods for lung ($p = 0.038$ for unadjusted; $p = 0.019$ for adjusted) and prostate cancer ($p = 0.001$ for unadjusted; $p = 0.01$ for adjusted). In lung cancer, survivors had a significantly higher adjusted prevalence of falls 1–2 years after diagnosis (28%, 95%CI, 21%–37%) ($p = 0.008$) compared to survivors 1–2 years before diagnosis (17%, 95%CI, 13%–21%). Adjusted fall prevalence for prostate cancer survivors was

significantly higher during years 1–2 (20%, 95%CI, 17%–24%) ($p < 0.001$), years 2–3 (19%, 95%CI, 16%–23%) ($p < 0.001$), and years 3–4 after diagnosis (17%, 95%CI, 14%–21%) ($p = 0.002$) in comparison with survivors during years 1–2 before diagnosis (12%, 95%CI, 10%–16%). Unadjusted and adjusted prevalence of falls did not differ significantly across time periods for other cancers.

3.3. Prevalence of Balance/Walking Problems in the Past 12 Months

As shown in Table 3, prevalence of balance/walking problems differed significantly across time periods in NHL ($p = 0.043$ for unadjusted; $p = 0.012$ for adjusted), breast ($p < 0.001$ for unadjusted; $p = 0.001$ for adjusted), lung ($p = 0.022$ for unadjusted; $p = 0.018$ for adjusted), and prostate cancer ($p < 0.001$ for unadjusted; $p = 0.012$ for adjusted). In breast cancer, adjusted prevalence of balance/walking problems was significantly higher during years 3–4 post-cancer diagnosis (41%, 95%CI, 36%–47%) ($p = 0.007$) than during years 1–2 pre-diagnosis (32%, 95%CI, 27%–38%). In lung cancer, adjusted prevalence was significantly higher within one year before cancer diagnosis (40%, 95%CI, 36%–46%) ($p = 0.006$) and during years 1–2 post-diagnosis (46%, 95%CI, 38%–56%) ($p = 0.005$) compared to during years 1–2 pre-diagnosis (33%, 95%CI, 28%–38%). Survivors of prostate cancer had significantly higher adjusted prevalence of balance/walking problems

Table 1
Characteristics of sample by cancer diagnosis.

Variables	Breast	Colorectal	Lung	Prostate	Bladder	Kidney	NHL	Uterine
Age at MHOS administration, mean (SD), y	75.4 (6.6)	77.3 (7.1)	75.9 (6.1)	74.2 (5.8)	77.5 (6.6)	75.3 (6.2)	76.8 (6.8)	75.0 (6.5)
Women, no. (%)	2268 (100)	773 (52.8)	760 (50.4)	0 (0)	176 (26.5)	180 (48.3)	252 (50.8)	359 (100)
Race, no. (%)								
White	1694 (74.7)	1086 (73.1)	1198 (78.3)	2312 (71.4)	594 (87.7)	281 (75.1)	415 (82.3)	297 (80.1)
Black	289 (12.7)	176 (11.8)	158 (10.3)	507 (15.7)	35 (5.2)	36 (9.6)	32 (6.3)	42 (11.3)
Other	285 (12.6)	224 (15.1)	174 (11.4)	418 (12.9)	48 (7.1)	57 (15.2)	57 (11.3)	32 (8.6)
Married, no. (%)	941 (42.0)	699 (48.1)	778 (51.9)	2328 (73.2)	392 (59.2)	217 (58.8)	272 (55.5)	150 (42.0)
Education, no. (%)								
<High school	517 (23.2)	467 (32.5)	510 (34.1)	785 (24.9)	170 (26.0)	96 (26.2)	139 (28.4)	86 (24.4)
High school	1366 (61.3)	743 (51.8)	823 (55.1)	1557 (49.4)	364 (55.7)	210 (57.4)	261 (53.3)	219 (62.0)
≥4 year college	345 (15.5)	225 (15.7)	161 (10.8)	809 (25.7)	120 (18.3)	60 (16.4)	90 (18.4)	48 (13.6)
Household income, no. (%)								
<\$30,000	1125 (49.6)	792 (53.3)	832 (54.4)	1355 (41.9)	309 (45.6)	178 (47.6)	246 (48.8)	177 (47.7)
\$30,000–50,000	365 (16.1)	209 (14.1)	249 (16.3)	711 (22.0)	146 (21.6)	61 (16.3)	96 (19.0)	54 (14.6)
>\$50,000	295 (13.0)	177 (11.9)	160 (10.5)	673 (20.8)	94 (13.9)	56 (15.0)	62 (12.3)	39 (10.5)
Unknown	483 (21.3)	308 (20.7)	289 (18.9)	498 (15.3)	128 (18.9)	79 (21.1)	100 (19.8)	101 (27.2)
Body mass index, mean (SD)	27.6 (6.0)	26.9 (5.5)	25.9 (5.4)	27.5 (4.5)	27.0 (4.8)	28.6 (6.1)	26.8 (5.1)	30.4 (7.6)
Comorbidity index, mean (SD)	3.1 (2.0)	3.0 (2.0)	3.5 (2.2)	2.6 (1.9)	3.1 (2.3)	3.3 (2.0)	3.1 (2.0)	2.8 (1.9)
Age at cancer diagnosis, mean (SD), y	73.9 (6.7)	75.9 (7.5)	75.5 (6.4)	72.5 (6.0)	76.2 (6.9)	73.9 (6.6)	75.7 (7.3)	73.5 (6.8)
Cancer stage, no. (%)								
In situ	420 (18.5)	78 (5.2)	a	a	375 (55.4)	6 (1.6)	a	a
Localized	1298 (57.2)	687 (46.2)	402 (26.3)	2845 (87.9)	257 (38.0)	256 (68.4)	161 (31.9)	268 (72.2)
Regional	491 (21.6)	565 (38.0)	420 (27.5)	288 (8.9)	34 (5.0)	69 (18.4)	86 (17.1)	76 (20.5)
Distant	59 (2.6)	156 (10.5)	707 (46.2)	103 (3.2)	11 (1.6)	43 (11.5)	257 (51.0)	25 (6.7)
Time of MHOS administration to cancer diagnosis, no. (%)								
1–2 year pre-diagnosis	391 (17.2)	293 (19.7)	463 (30.3)	491 (15.2)	138 (20.4)	66 (17.6)	112 (22.2)	66 (17.8)
0–1 year pre-diagnosis	636 (28.0)	409 (27.5)	691 (45.2)	767 (23.7)	202 (29.8)	124 (33.2)	167 (33.1)	99 (26.7)
1–2 year post-diagnosis	425 (18.7)	292 (19.7)	164 (10.7)	648 (20.0)	121 (17.9)	59 (15.8)	93 (18.5)	73 (19.7)
2–3 year post-diagnosis	425 (18.7)	246 (16.6)	127 (8.3)	672 (20.8)	111 (16.4)	60 (16.0)	63 (12.5)	69 (18.6)
3–4 year post-diagnosis	391 (17.2)	246 (16.6)	85 (5.6)	659 (20.4)	105 (15.5)	65 (17.4)	69 (13.7)	64 (17.3)
Radiation, no. (%)	1096 (49.5)	141 (9.6)	490 (32.5)	1397 (43.9)	21 (3.1)	13 (3.5)	96 (19.3)	124 (34.0)
Surgery, no. (%)	2150 (94.9)	1360 (91.7)	438 (28.7)	930 (29.1)	639 (94.7)	309 (83.1)	153 (31.2)	353 (95.1)
Radiation & surgery, no. (%)	1084 (47.8)	114 (7.7)	82 (5.4)	75 (2.3)	18 (2.7)	a	36 (7.1)	119 (32.1)

Abbreviations: MHOS, Medicare Health Outcomes Survey; NHL, Non-Hodgkin's lymphoma; a indicates cell number <11.

during years 1–2 (29%, 95%CI, 26%–33%) ($p = 0.004$), years 2–3 (28%, 95%CI, 25%–32%) ($p = 0.012$), and years 3–4 post-cancer diagnosis (29%, 95%CI, 25%–33%) ($p = 0.006$) than during years 1–2 pre-diagnosis (22%, 95%CI, 18%–26%). In NHL, adjusted prevalence were significantly higher within the second year after cancer diagnosis (45%, 95%CI, 34%–59%) ($p = 0.005$) compared to during years 1–2 pre-diagnosis

Table 2
Unadjusted and adjusted^c prevalence of survivors with falls in the past 12 months by time to cancer diagnosis.

Diagnosis	No. of survivors	Unadjusted prevalence of survivors with falls, % (95%CI)					p-Value ^a
		1–2 year pre-diagnosis [Reference]	0–1 year pre-diagnosis	1–2 year post-diagnosis	2–3 year post-diagnosis	3–4 year post-diagnosis	
Breast	2223	23 (19–27)	23 (20–27)	25 (21–30)	26 (25–30)	29 (25–34)	0.219
Colorectal	1463	25 (20–30)	24 (20–28)	27 (22–33)	26 (21–32)	20 (16–26)	0.446
Lung	1489	18 (15–22)	23 (20–27)	29 (23–37) ^b	25 (18–34)	27 (19–39)	0.038
Prostate	3183	13 (10–16)	16 (14–19)	22 (19–25) ^b	21 (18–24) ^b	19 (17–23) ^b	0.001
Bladder	664	26 (20–35)	25 (20–32)	26 (19–36)	28 (21–38)	23 (16–33)	0.944
Kidney	370	26 (17–39)	18 (12–16)	24 (15–38)	17 (10–30)	22 (14–35)	0.622
NHL	502	21 (14–30)	24 (18–31)	26 (18–36)	27 (18–41)	23 (15–36)	0.885
Uterine	364	31 (22–45)	25 (18–35)	24 (16–36)	22 (14–35)	27 (18–41)	0.788
Diagnosis	No. of survivors	Adjusted prevalence of survivors with falls, % (95%CI)					p-Value ^a
		1–2 year pre-diagnosis [Reference]	0–1 year pre-diagnosis	1–2 year post-diagnosis	2–3 year post-diagnosis	3–4 year post-diagnosis	
Breast	2181	20 (16–25)	21 (18–25)	23 (19–27)	23 (19–27)	25 (21–31)	0.392
Colorectal	1405	22 (17–27)	21 (17–26)	25 (20–31)	25 (20–31)	17 (13–23)	0.189
Lung	1452	17 (13–21)	21 (18–26)	28 (21–37) ^b	24 (17–33)	25 (17–36)	0.019
Prostate	3095	12 (10–16)	16 (13–19)	20 (17–24) ^b	19 (16–23) ^b	17 (14–21) ^b	0.010
Bladder	640	23 (16–34)	23 (16–32)	24 (16–36)	25 (17–37)	19 (12–30)	0.835
Kidney	362	19 (11–33)	12 (7–20)	19 (12–31)	12 (6–24)	18 (11–31)	0.303
NHL	482	19 (12–29)	21 (14–31)	25 (16–38)	25 (16–41)	21 (12–36)	0.789
Uterine	345	28 (16–47)	24 (15–38)	22 (14–35)	21 (13–35)	26 (15–45)	0.900

Abbreviation: NHL, non-Hodgkin's lymphoma.

^a p-Values are for the main effect of time periods in the regression model for each cancer diagnosis.

^b Each superscript letter indicates that the prevalence during a time period differed significantly from the reference prevalence during 1–2 years pre-diagnosis. Bonferroni adjustment was applied for multiple comparisons of time periods with significance level at $p < 0.0125$.

^c Model for adjusted prevalence estimates included time periods and demographics covariates (age at survey, race, education, marital status, and household income). Gender was also included in the models for colorectal, lung, bladder and kidney cancer, and NHL.

Table 3
Unadjusted and adjusted^c prevalence of survivors with balance or walking problems in the past 12 months by time to cancer diagnosis.

Diagnosis	No. of survivors	Unadjusted prevalence of survivors with balance or walking problems, % (95%CI)					p-Value ^a
		1-2 year pre-diagnosis [Reference]	0-1 year pre-diagnosis	1-2 year post-diagnosis	2-3 year post-diagnosis	3-4 year post-diagnosis	
Breast	2215	33 (29–38)	30 (27–34)	39 (34–44)	39 (34–43)	43 (39–49) ^b	<0.001
Colorectal	1463	36 (31–42)	34 (30–39)	36 (31–42)	38 (32–45)	37 (31–43)	0.864
Lung	1489	33 (29–37)	41 (38–45) ^b	45 (38–54) ^b	42 (34–52)	42 (32–54)	0.022
Prostate	3176	20 (17–24)	23 (20–26)	29 (26–33) ^b	29 (26–32) ^b	30 (26–33) ^b	<0.001
Bladder	663	33 (26–42)	34 (28–42)	27 (20–36)	39 (31–50)	34 (26–44)	0.421
Kidney	370	30 (21–44)	35 (28–45)	42 (31–57)	40 (29–54)	46 (35–60)	0.377
NHL	498	27 (20–37)	34 (28–42)	47 (38–58) ^b	39 (29–54)	43 (33–57)	0.043
Uterine	350	37 (27–51)	31 (23–42)	44 (34–58)	34 (25–48)	48 (37–62)	0.209

Diagnosis	No. of survivors	Adjusted prevalence of survivors with balance or walking problems, % (95%CI)					p-Value ^a
		1-2 year pre-diagnosis [Reference]	0-1 year pre-diagnosis	1-2 year post-diagnosis	2-3 year post-diagnosis	3-4 year post-diagnosis	
Breast	2174	32 (27–38)	30 (26–34)	38 (33–43)	36 (31–42)	41 (36–47) ^b	0.001
Colorectal	1404	33 (28–39)	29 (25–34)	34 (29–40)	35 (29–42)	35 (29–42)	0.383
Lung	1452	33 (28–38)	40 (36–46) ^b	46 (38–56) ^b	43 (34–53)	43 (33–55)	0.018
Prostate	3088	22 (18–26)	24 (21–28)	29 (26–33) ^b	28 (25–32) ^b	29 (25–33) ^b	0.012
Bladder	639	40 (30–52)	41 (32–52)	31 (23–43)	44 (33–57)	39 (28–53)	0.461
Kidney	362	35 (23–51)	37 (28–48)	46 (33–63)	42 (30–60)	52 (39–69)	0.280
NHL	479	26 (19–37)	30 (22–39)	45 (34–59) ^b	41 (29–57)	42 (30–59)	0.012
Uterine	340	37 (25–53)	30 (21–44)	46 (34–62)	33 (23–49)	49 (34–68)	0.127

Abbreviation: NHL, non-Hodgkin's lymphoma.

^a p-Values are for the main effect of time periods in the regression model for each cancer diagnosis.

^b Each superscript letter indicates that the prevalence during a time period differed significantly from the reference prevalence during 1–2 years pre-diagnosis. Bonferroni adjustment was applied for multiple comparisons of time periods with significance level at $p < 0.0125$.

^c Model for adjusted prevalence estimates included time periods and demographics covariates (age at survey, race, education, marital status, and household income). Gender was also included in the models for colorectal, lung, bladder and kidney cancer, and NHL.

(26%, 95%CI, 19%–37%). For all other cancers, unadjusted and adjusted prevalence of balance/walking problems did not differ significantly across time periods.

4. Discussion

This study is the first to examine the prevalence of self-reported falls and balance/walking problems in the past 12 months from pre- to post-cancer diagnosis among older survivors of eight common cancers using population-based data and a cross-sectional design. Current findings indicated that prevalence increased post-diagnosis compared to 1–2 years pre-diagnosis in some but not all cancers. To address falls and balance/walking problems, particularly in survivors of cancers with increased prevalence post-diagnosis, clinicians may integrate rehabilitation services in survivorship care planning.

Findings from this study contribute to knowledge gaps in important ways. First, by analyzing nationally representative data, we demonstrated time-variant prevalence of falls and balance/walking problems before and after cancer diagnosis in non-Hodgkin's lymphoma, breast, prostate, and lung cancer. Previous research grouped different types of cancer together [17,46,47], combined data from individuals who had survived cancer for any length of time [17,35,36,46–48], or included only post-diagnosis data; [17,35,36,46–48] thus, differences in prevalence by time to cancer diagnosis within each cancer were likely masked. In a study of fall rates among older cancer survivors using the SEER-MHOS data, long-term (≥5 years) survivors accounted for 68% of the sample [17]. In contrast, we estimated the prevalence with each cancer using cross-sectional data across six time periods, from 2 years before cancer diagnosis to 4 years after diagnosis. Because the MHOS asked about falls and balance/walking problems in the past 12 months, survivors in the time period of 0–1 year post-diagnosis could have fallen or experienced balance/walking problems before the diagnosis. For example, a survivor completed the MHOS at 6 months post-diagnosis could have fallen 6 months before diagnosis. However, according to the fall prevention guidelines by the American Geriatric Society, clinicians should ask all older adults about falls in the past year and difficulty with balance or

walking [19]. Moreover, a history of falls is a significant risk factor for future falls among older cancer survivors [46]. In this context, current findings are relevant to the recommended practice by American Geriatric Society, and support the need to ask these same questions when treating older cancer survivors, particularly those with cancers demonstrating higher prevalence during initial time periods post-diagnosis. The extent to which symptoms and changes in body functions associated with cancer impact falls and balance/walking performance before a clinical diagnosis of cancer was confirmed remains to be investigated.

Second, prevalence of falls was higher post-cancer diagnosis in lung and prostate cancer while balance/walking problems were more prevalent after diagnosis among survivors of breast, prostate, lung cancer, and NHL. Therefore, the screening, surveillance, and interventions to reduce falls and balance/walking problems could be different depending on the type of problems and the cancer diagnosis. Research evidence has revealed a lack of awareness about falls and balance/walking problems among oncology providers. According to the American Geriatrics Society [19], healthcare providers should ask older adults during all encounters whether they have had falls or difficulty with balance or walking [19]. However, a study reviewing medical records showed that only 10% of older cancer survivors with one or more falls in the past 6 months had appropriate medical documentation about their falls [49]. In another study in an oncology outpatient setting, no referrals to rehabilitation specialists were made to address difficulty with balance or walking, the most frequent functional problem identified by cancer survivors being treated at the clinic [36]. Our findings inform the development of a prospective surveillance model (PSM) that specifies time points to provide patient education, detect and treat impairments associated with cancer and its treatment, and enhance awareness and access to rehabilitation [50,51]. The PSM has been proposed for rehabilitation of women with breast cancer to improve physical and functional outcomes [50–52]. Similarly, a PSM may guide clinicians to provide interventions to prevent falls, and improve balance or walking ability among older cancer survivors.

Prevalence of falls among cancer survivors reported previously varied widely [53]. Percentages of cancer survivors with falls were

18%–27% during inpatient stay and 18%–65% in outpatient settings [54–56]. In population-based studies, falls occurred in 25%–33% of older cancer survivors over 3 to 12 months [57–59]. Divergent fall rates reported in the literature may be associated with study design, sample characteristics, follow-up durations, and assessment methods of falls [36]. Overall, in this study, prevalence estimates of falls are in line with previous findings. Additionally, except for lung and prostate cancer, prevalence of falls for other cancers remained unchanged over time. Previous research of older survivors of any cancer reported no differences in fall rates with time since cancer diagnosis [34]. In older adults, lung cancer has a poor prognosis, with an estimated 5-year survival rate of 16% [60], in contrast to 62% in NHL, 99% in prostate, and 89% in breast cancer [60]. Current findings likely reflect the disease burden and the impact of cancer treatment on survivors of lung cancer and NHL, who were mostly diagnosed at a more advanced stage. Moreover, survivors' functional status may influence treatment choice [61] and vice versa [62]. Prostate cancer survivors with radiotherapy had significant declines in physical function between 12 and 52 months after treatment, whereas those with prostatectomy improved slightly [62]. Whether variations in prevalence across different time periods after cancer diagnosis are linked to the effects of cancer treatment or disease progression cannot be directly assessed in this study. The SEER-MHOS linkage does not have information on chemotherapy, hormonal treatment, or other prescription drugs, although more advanced cancer is likely to be treated with chemotherapy [37]. The time when a condition developed cannot be ascertained from MHOS data [37]. Future research is needed to delineate the influence of cancer-related factors on falls.

Research of self-reported difficulty with balance or walking in cancer survivors is limited. In a population-based study, about 37% of older cancer survivors reported “yes” to the question “How often do you have difficulty with balance?” [46]. The recovery of walking ability over time was reported in another population-based study of older cancer survivors. Difficulty with walking 1/2 mile was most prevalent in recent older cancer survivors (<2 years post-cancer diagnosis) (32%), compared to short-term survivors (2–5 years post-diagnosis) (28%), long-term survivors (≥5 years post-diagnosis) (26%), or non-cancer controls (19%) [63]. We found that adjusted prevalence of balance/walking problems across time periods post-diagnosis was greater than 30% in all cancers, except for prostate cancer. Balance/walking problems became evident within one year before diagnosis of lung cancer, suggesting that these functional problems predated the clinical diagnosis and treatment. In breast cancer, balance/walking problems were most prevalent during years 3–4 post-diagnosis. Longer-term surveillance of these functions is warranted for breast cancer survivors. While survivors of other cancers regained balance or walking ability after cancer diagnosis, current findings reflect the inherent heterogeneity of cancer survivorship across cancers.

In addition to the lack of cancer treatment information, other than surgery and radiation, the SEER-MHOS dataset has other limitations [37,64]. First, falls in the past 12 months were based on self-report, which may be subject to recall bias [65] and underreporting [66,67]. Older adults may not recognize the severity or the definition of a fall, or may not remember a fall [66,67]. While a history of falls is a significant predictor of future falls in older cancer survivors [29,68], the SEER-MHOS does not collect the number of falls experienced by each responder. Second, there may be a lack of representativeness in the Medicare program. The medical claims data are not available. The MHOS collects data from the Medicare Advantage enrollees in the SEER regions only and excludes Medicare beneficiaries with fee-for-service coverage, a population that had been found to have more risk factors and lower function [69]. Nevertheless, the SEER-MHOS linkage provides population-based, patient-reported outcomes data that are important to research of cancer survivorship [64].

This study has other weakness. The cross-sectional design makes it difficult to interpret the relationships identified. The prevalence estimates may be biased if characteristics of survivors at the pre-diagnosis

time periods were different from those at post-diagnosis time periods. For example, individuals at earlier stages of cancer or higher levels of function before cancer diagnosis may be more likely to survive longer. Cross-sectional data at later time periods post-cancer diagnosis may be comprised of healthier survivors who have lived longer. Further studies using a longitudinal design are necessary to investigate the cause–effect relationships between potential risk factors and falls or balance/walking problems before and after cancer diagnosis among older survivors.

5. Conclusions

Among older survivors of eight common cancers, there is a high prevalence of falls and difficulty with balance or walking after cancer diagnosis in some cancers. Current findings underscore the urgency in implementing mechanisms for surveillance, screening, and interventions to prevent and reduce functional problems along the trajectory of cancer survivorship for older adults.

Disclosures and Conflict of Interest Statements

The authors have no conflicts of interest to disclose.

Author Contributions

Study Concept: MH Huang

Study Design: MH Huang, J Blackwood, L Pfalzer

Data Acquisition: MH Huang

Quality Control of Data and Algorithms: MH Huang, M Godoshian

Data Analysis and Interpretation: MH Huang, L Pfalzer

Statistical Analysis: MH Huang

Manuscript Preparation: MH Huang, L Pfalzer

Manuscript Editing: MH Huang, J Blackwood, M Godoshian, L Pfalzer

Manuscript Review: MH Huang, J Blackwood, M Godoshian, L Pfalzer

References

- [1] Cancer Statistics Center: American Cancer Society. Cited 2016 December 12. Available from: <http://www.cancer.org/research/cancerfactsstatistics/>; 2016.
- [2] National Cancer Institute. SEER cancer statistics factsheets Bethesda, MD [cited 2016 December 12]. Available from: <http://seer.cancer.gov/statfacts/html/all.html>.
- [3] Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER cancer statistics review, 1975–2011. April 2014 ed. Bethesda, MD: National Cancer Institute; 2014.
- [4] DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. *CA* 2014;64:252–71.
- [5] National Cancer Institute. Cancer statistics 2016. [cited 2016 December 12]. Available from: <http://www.cancer.gov/about-cancer/what-is-cancer/statistics>.
- [6] Avis NE, Deimling GT. Cancer survivorship and aging. *Cancer* 2008;113S:3519–29.
- [7] Stubblefield MD, Schmitz KH, Ness KK. Physical functioning and rehabilitation for the cancer survivor. *Semin Oncol* 2013;40:784–95.
- [8] Smith SR, Reish AG, Andrews C. Cancer survivorship: a growing role for psychiatric care. *PMR* 2015;7:527–31.
- [9] Rowland JH, Bellizzi KM. Cancer survivorship issues: life after treatment and implications for an aging population. *J Clin Oncol* 2014;32:2662–8.
- [10] Stevens JA, Corso PS, Finkelstein EA, Miller TR. The costs of fatal and non-fatal falls among older adults. *Inj Prev* 2006;12:290–5.
- [11] Dellinger AM, Stevens JA. The injury problem among older adults: mortality, morbidity and costs. *J Saf Res* 2006;37:519–22.
- [12] Stevens JA, Mack KA, Paulozzi LJ, Ballesteros MF. Self-reported falls and fall-related injuries among persons aged ≥65 years—United States, 2006. *J Saf Res* 2008;39:345–9.
- [13] Hawkins K, Musich S, Ozminowski RJ, Bai M, Migliori RJ, Yeh CS. The burden of falling on the quality of life of adults with Medicare supplement insurance. *J Gerontol Nurs* 2011;37:36–47.
- [14] Friedman SM, Munoz B, West SK, Rubin GS, Fried LP. Falls and fear of falling: which comes first? A longitudinal prediction model suggests strategies for primary and secondary prevention. *J Am Geriatr Soc* 2002;50:1329–35.
- [15] Vellas BJ, Wayne SJ, Romero LJ, Baumgartner RN, Garry PJ. Fear of falling and restriction of mobility in elderly fallers. *Age Ageing* 1997;26:189–93.
- [16] Shumway-Cook A, Ciol MA, Hoffman J, Dudgeon BJ, Yorkston K, Chan L. Falls in the Medicare population: incidence, associated factors, and impact on health care. *Phys Ther* 2009;89:324–32.

- [17] Pandya C, Magnuson A, Dale W, Lowenstein L, Fung C, Mohile SG. Association of falls with health-related quality of life (HRQOL) in older cancer survivors: a population based study. *J Geriatr Oncol* 2016;7:201–10.
- [18] Groessl EJ, Kaplan RM, Rejeski WJ, Katula JA, King AC, Frierson G, et al. Health-related quality of life in older adults at risk for disability. *Am J Prev Med* 2007;33(3):214–8.
- [19] Summary of the updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. *J Am Geriatr Soc* 2011; 59(1):148–57.
- [20] Muir SW, Berg K, Chesworth B, Klar N, Speechley M. Balance impairment as a risk factor for falls in community-dwelling older adults who are high functioning: a prospective study. *Phys Ther* 2010;90(3):338–47.
- [21] Bürge E, von Gunten A, Berchtold A. Factors favoring a degradation or an improvement in activities of daily living (ADL) performance among nursing home (NH) residents: a survival analysis. *Arch Gerontol Geriatr* 2013;56(1):250–7.
- [22] Winters-Stone KM, Torgirimson B, Horak F, Eisner A, Nail L, Leo MC, et al. Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach. *Arch Phys Med Rehabil* 2011;92(4):646–52.
- [23] Kolb NA, Smith A, Singleton J, Beck SL, Stoddard GJ, Brown S, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. *JAMA Neurol* 2016;73(7):860–6.
- [24] Brown JC, Harhay MO, Harhay MN. Physical function as a prognostic biomarker among cancer survivors. *Br J Cancer* 2015;112(1):194–8.
- [25] Klepin HD, Geiger AM, Tooze JA, Newman AB, Colbert LH, Bauer DC, et al. Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. *J Am Geriatr Soc* 2010;58: 76–82.
- [26] Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc* 2010;42:1409–26.
- [27] Tan HJ, Saliba D, Kwan L, Moore AA, Litwin MS. Burden of geriatric events among older adults undergoing major cancer surgery. *J Clin Oncol* 2016;34:1231–8.
- [28] Williams GR, Deal AM, Nyrop KA, Pergolotti M, Guerard EJ, Jolly TA, et al. Geriatric assessment as an aide to understanding falls in older adults with cancer. *Support Care Cancer* 2015;23:2273–80.
- [29] Wildes TM, Dua P, Fowler SA, Miller JP, Carpenter CR, Avidan MS, et al. Systematic review of falls in older adults with cancer. *J Geriatr Oncol* 2015;6:70–83.
- [30] Hudson MM, Oeffinger KC, Jones K, Brinkman TM, Krull KR, Mulrooney DA, et al. Age-dependent changes in health status in the childhood cancer survivor cohort. *J Clin Oncol* 2015;33:479–91.
- [31] Campbell KL, Pusic AL, Zucker DS, McNeely ML, Binkley JM, Cheville AL, et al. A prospective model of care for breast cancer rehabilitation: function. *Cancer* 2012; 118(S8):2300–11.
- [32] Ness KK, Wall MM, Oakes JM, Robison LL, Gurney JG. Physical performance limitations and participation restrictions among cancer survivors: a population-based study. *Ann Epidemiol* 2006;16:197–205.
- [33] Henderson TO, Ness KK, Cohen HJ. Accelerated aging among cancer survivors: from pediatrics to geriatrics. American Society of Clinical Oncology educational book. American Society of Clinical Oncology meeting; 2014. p. e423–30.
- [34] Spoelstra SL, Given BA, Schutte DL, Sikorskii A, You M, Given CW. Do older adults with cancer fall more often? A comparative analysis of falls in those with and without cancer. *Oncol Nurs Forum* 2013;40:E69–78.
- [35] Mohile SG, Fan L, Reeve E, Jean-Pierre P, Mustian K, Peppone L, et al. Association of cancer with geriatric syndromes in older Medicare beneficiaries. *J Clin Oncol* 2011; 29:1458–64.
- [36] Cheville AL, Beck LA, Petersen TL, Marks RS, Gamble GL. The detection and treatment of cancer-related functional problems in an outpatient setting. *Support Care Cancer* 2009;17:61–7.
- [37] Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB. Overview of the SEER–Medicare health outcomes survey linked dataset. *Health Care Financ Rev* 2008;29:5–21.
- [38] Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER–MHOS linkage. *Cancer* 2015;121:758–65.
- [39] McCall N, Khatutsky G, Smith K, Pope GC. Estimation of non-response bias in the Medicare FFS HOS. *Health Care Financ Rev* 2004;25:27–41.
- [40] Surveillance, epidemiology, and end results (SEER) program SEER*stat database. National Cancer Institute D, Surveillance Research Program, Surveillance Systems Branch; 2014.
- [41] Surveillance E, and end results (SEER) program localized/regional/distant stage adjustments: surveillance research program. [cited 2016 December 12]. Available from: <https://seer.cancer.gov/seerstat/variables/seer/lrd-stage/>.
- [42] Zou G. A modified Poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004;159:702–6.
- [43] Frome EL, Checkoway H. Epidemiologic programs for computers and calculators. Use of Poisson regression models in estimating incidence rates and ratios. *Am J Epidemiol* 1985;121:309–23.
- [44] Clegg LX, Gail MH, Feuer EJ. Estimating the variance of disease-prevalence estimates from population-based registries. *Biometrics* 2002;58:684–8.
- [45] Gale CR, Cooper C, Sayer AA. Prevalence and risk factors for falls in older men and women: The English Longitudinal Study of Ageing. *Age Ageing* 2016;45:789–94.
- [46] Chen TY, Janke MC. Predictors of falls among community-dwelling older adults with cancer: results from the health and retirement study. *Support Care Cancer* 2014;22: 479–85.
- [47] Chen Z, Maricic M, Aragaki AK, Mouton C, Arendell L, Lopez AM, et al. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. *Osteoporos Int* 2009;20:527–36.
- [48] Chen W, Shi J, Qian L, Azen SP. Comparison of robustness to outliers between robust poisson models and log-binomial models when estimating relative risks for common binary outcomes: a simulation study. *BMC Med Res Methodol* 2014;14:82.
- [49] Guerard EJ, Deal AM, Williams GR, Jolly TA, Nyrop KA, Muss HB. Falls in older Adults with cancer: evaluation by oncology providers. *J Oncol Pract* 2015;11:470–4.
- [50] Stout NL, Binkley JM, Schmitz KH, Andrews K, Hayes SC, Campbell KL, et al. A prospective surveillance model for rehabilitation for women with breast cancer. *Cancer* 2012;118(8 Suppl):2191–200.
- [51] Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, et al. Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. *Cancer* 2012; 118(S8):2207–16.
- [52] Levy EW, Pfalzer LA, Danoff J, Springer BA, McGarvey C, Shieh CY, et al. Predictors of functional shoulder recovery at 1 and 12 months after breast cancer surgery. *Breast Cancer Res Treat* 2012;134:315–24.
- [53] Sattar S, Alibhai SM, Spoelstra SL, Fazelzad R, Puts MT. Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment. *Support Care Cancer* 2016;24:4459–69.
- [54] Capone LJ, Albert NM, Bena JF, Tang AS. Predictors of a fall event in hospitalized patients with cancer. *Oncol Nurs Forum* 2012;39:E407–15.
- [55] Pautex S, Herrmann FR, Zulian GB. Factors associated with falls in patients with cancer hospitalized for palliative care. *J Palliat Med* 2008;11:878–84.
- [56] Goodridge D, Marr H. Factors associated with falls in an inpatient palliative care unit: an exploratory study. *Int J Palliat Nurs* 2002;8:548–56.
- [57] Potter P, Olsen S, Kuhrik M, Kuhrik N, Huntley LR. A DVD program on fall prevention skills training for cancer family caregivers. *J Cancer Educ* 2012;27:83–90.
- [58] Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. *J Clin Oncol* 2011;29:3457–65.
- [59] Overcash JA, Rivera Jr HR. Physical performance evaluation of older cancer patients: a preliminary study. *Crit Rev Oncol Hematol* 2008;68:233–41.
- [60] NNA Howlader, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2013. Bethesda, MD: National Cancer Institute; 2016 [based on November 2015 SEER data submission, posted to the SEER web site, Available from: http://seer.cancer.gov/csr/1975_2013/].
- [61] Jacobs BL, Lopa SH, Yabes JG, Nelson JB, Barnato AE, Degenholtz HB. Association of functional status and treatment choice among older men with prostate cancer in the Medicare advantage population. *Cancer* 2016;122:3199–206.
- [62] Korfage JJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. *Int J Cancer* 2005;116:291–6.
- [63] Sweeney C, Schmitz KH, Lazovich D, Virnig BA, Wallace RB, Folsom AR. Functional limitations in elderly female cancer survivors. *J Natl Cancer Inst* 2006;98:521–9.
- [64] Kent EE, Malinoff R, Rozjabek HM, Ambs A, Clauser SB, Topor MA, et al. Revisiting the surveillance epidemiology and end results cancer registry and medicare health outcomes survey (SEER–MHOS) linked data resource for patient-reported outcomes research in older adults with cancer. *J Am Geriatr Soc* 2016;64:186–92.
- [65] Hale WA, Delaney MJ, Cable T. Accuracy of patient recall and chart documentation of falls. *J Am Board Fam Pract* 1993;6:239–42.
- [66] Freiburger E, de Vreede P. Falls recall—limitations of the most used inclusion criteria. *Eur Rev Aging Phys Act* 2011;8:105–8.
- [67] Hannan MT, Gagnon MM, Aneja J, Jones RN, Cupples LA, Lipsitz LA, et al. Optimizing the tracking of falls in studies of older participants: comparison of quarterly telephone recall with monthly falls calendars in the MOBILIZE Boston study. *Am J Epidemiol* 2010;171:1031–6.
- [68] Walle NV, Kenis C, Heeren P, Van Puyvelde K, Decoster L, Beyer I, et al. Fall predictors in older cancer patients: a multicenter prospective study. *BMC Geriatr* 2014;14:1.
- [69] Riley G. Two-year changes in health and functional status among elderly Medicare beneficiaries in HMOs and fee-for-service. *Health Serv Res* 2000;35:44–59.